How to build anti-PD1 agonist antibodies

被引：0
|
作者：
Flemming, Alexandra
机构：
[1] Nature Reviews Immunology,
来源：
NATURE REVIEWS IMMUNOLOGY | 2023年 / 23卷 / 03期
关键词：
D O I：
10.1038/s41577-023-00844-2
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
A paper in Science Immunology describes the crucial features of agonist antibodies to the checkpoint molecule PD1.
引用
收藏
页码：139 / 139
页数：1
相关论文
共 50 条
  • [21] CIRCULATING TUMOR DNA AS A BIOMARKER IN METASTATIC MELANOMA PATIENTS TREATED WITH ANTI-PD1 ANTIBODIES
    Lee, J.
    Boyd, S.
    Tembe, V.
    Menzies, A.
    Long, G.
    Guminski, A.
    Kefford, R.
    Carlino, M.
    Rizos, H.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 48 - 49
  • [22] Complete responders to anti-PD1 antibodies. What happens when we stop?
    Atkinson, V. G.
    Ladwa, R.
    ANNALS OF ONCOLOGY, 2016, 27
  • [23] SAFETY AND EFFICACY OF ANTI-PD1 ANTIBODIES IN THE ELDERLY POPULATION WITH METASTATIC MELANOMA AT THE CANBERRA HOSPITAL
    Randhawa, M.
    Rai, R.
    Nguyen, B.
    Ali, S.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 67 - 67
  • [24] Risk of Relapse after Anti-PD1 Discontinuation and Efficacy of Anti-PD1 Re-Treatment in Patients with Hodgkin Lymphoma
    Manson, Guillaume
    Brice, Pauline
    Herbaux, Charles
    Silva, Maria
    Bouabdallah, Krimo
    Deau-Fisher, Benedicte
    Bouteloup, Juliette
    de Collela, Jean Marc Schiano
    Nicolas-Virelizier, Emmanuelle
    Maerevoet, Marie
    Ghesquieres, Herve
    Bastard, Aspasia Stamatoulas
    Antier, Chloe
    Poizeau, Florence
    Dercle, Laurent
    Houot, Roch
    BLOOD, 2019, 134
  • [25] Distribution of anti-PD1/PDL1 autoantibodies in multiple cancer types and potential biomarker role for anti-PD1 therapy
    Tan, Q.
    Wang, Y.
    Liu, S.
    Luo, R.
    Wang, S.
    Liang, T.
    Yang, J.
    Xing, P.
    Yao, J.
    Wu, D.
    Zhang, Z.
    Dai, J.
    Yu, X.
    Han, X.
    Shi, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S1097 - S1098
  • [26] Efficacy of anti-PD1 re-treatment in patients with Hodgkin lymphoma who relapsed after anti-PD1 discontinuation
    Manson, Guillaume
    Brice, Pauline
    Herbaux, Charles
    Bouabdallah, Kamal
    Antier, Chloe
    Poizeau, Florence
    Dercle, Laurent
    Houot, Roch
    HAEMATOLOGICA, 2020, 105 (11) : 2664 - 2666
  • [27] Anti-PD1/PDL1 induced psoriasis
    Voudouri, D.
    Nikolaou, V.
    Laschos, K.
    Charpidou, A.
    Soupos, N.
    Triantafyllopoulou, I.
    Panoutsopoulou, I.
    Tsimpoukis, S.
    Aravantinos, G.
    Syrigos, K.
    Stratigos, A. J.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 : 53 - 54
  • [28] Impact of anti-PD1 on TIL phenotype and function
    Creasy, Caitlin
    Haymaker, Cara
    Forget, Marie-Andree
    Singh, Gopal
    Tapia, Coya
    Painter, Jeane Marie
    Meric-Bernstam, Funda
    Bernatchez, Chantale
    Naing, Aung
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [29] Kinase inhibition and anti-PD1 combination therapy
    Collingridge, David
    LANCET ONCOLOGY, 2020, 21 (07): : 886 - 886
  • [30] Anti-PD1/PDL1 induced psoriasis
    Voudouri, Dimitra
    Nikolaou, Vasiliki
    Laschos, Konstantinos
    Charpidou, Andriani
    Soupos, Nikolaos
    Triantafyllopoulou, Ioanna
    Panoutsopoulou, Ioanna
    Aravantinos, Gerasimos
    Syrigos, K.
    Stratigos, A.
    CURRENT PROBLEMS IN CANCER, 2017, 41 (06) : 407 - 412
12345